By Christy Santhosh and Kamal Choudhury Jan 22 (Reuters) - Abbott forecast current-quarter profit below estimates after ...

Abbott reports fourth-quarter sales that miss analysts’ estimates.

Abbott Laboratories saw its shares down 10% at the end of trading Thursday, Jan. 22, as the market digested weaknesses from its fourth-quarter and full-year earnings report. | Abbott Laboratories saw ...

Healthcare product and device company Abbott Laboratories (NYSE:ABT) missed Wall Street’s revenue expectations in Q4 CY2025 ...

Abbott guided first-quarter earnings below expectations after promotions weighed on nutrition sales and margins.

Abbott Laboratories reported Q4 2025 sales of $11.46 billion, an increase of 4.4% from the previous year but falling short of analyst projections by approximately 3%. The adjusted EPS was $1.50, ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott shares sank 8% as Q4 revenue of $11.5B missed the $11.8B target, with nutrition sales dropping 8.9% on price ...

Pricing challenges in Abbott’s nutrition business and lower than expected sales of continuous glucose monitors drove down the ...

Abbott's fourth quarter revenue missed expectations in its devices, diagnostics and nutrition segments, while staying in line for its established pharmaceutical business.